Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply

Lancet Oncol. 2021 Aug;22(8):e346. doi: 10.1016/S1470-2045(21)00418-6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Glioma* / drug therapy
  • Glioma* / genetics
  • Humans
  • Isocitrate Dehydrogenase
  • Temozolomide / adverse effects

Substances

  • Isocitrate Dehydrogenase
  • Temozolomide